124 related articles for article (PubMed ID: 35395697)
1. Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjects.
Hwang JG; Lee S; Huh W; Han J; Oh J; Jang IJ; Yu KS
Br J Clin Pharmacol; 2022 Sep; 88(9):4100-4110. PubMed ID: 35395697
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium-glucose cotransporter 2 inhibitor and metformin in healthy subjects.
Kim B; Huh KY; Hwang JG; Nah J; Huh W; Cho JM; Jang IJ; Yu KS; Kim Y; Lee S
Br J Clin Pharmacol; 2023 Apr; 89(4):1462-1470. PubMed ID: 36422809
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
Jeong SI; Kim Y; Nah JJ; Huh W; Jang IJ; Hwang JG; Lee S
Br J Clin Pharmacol; 2023 Jun; 89(6):1780-1788. PubMed ID: 36496349
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects.
Yoon S; Park MS; Jin BH; Shin H; Na J; Huh W; Kim CO
Expert Opin Drug Metab Toxicol; 2023; 19(7):479-485. PubMed ID: 37593838
[TBL] [Abstract][Full Text] [Related]
7. Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Veltkamp SA; Kadokura T; Krauwinkel WJ; Smulders RA
Clin Drug Investig; 2011 Dec; 31(12):839-51. PubMed ID: 21877761
[TBL] [Abstract][Full Text] [Related]
8. Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Henagliflozin, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter 2, in Healthy Subjects Following Single- and Multiple-dose Administration.
Zhang YF; Liu YM; Yu C; Wang YT; Zhan Y; Liu HY; Zou JJ; Jia JY; Chen Q; Zhong DF
Clin Ther; 2021 Feb; 43(2):396-409. PubMed ID: 33454124
[TBL] [Abstract][Full Text] [Related]
9. Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin.
Choi MK; Nam SJ; Ji HY; Park MJ; Choi JS; Song IS
Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32183468
[TBL] [Abstract][Full Text] [Related]
10. First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Kapur A; O'Connor-Semmes R; Hussey EK; Dobbins RL; Tao W; Hompesch M; Smith GA; Polli JW; James CD; Mikoshiba I; Nunez DJ
BMC Pharmacol Toxicol; 2013 May; 14():26. PubMed ID: 23668634
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects.
Chen X; Hu P; Vaccaro N; Polidori D; Curtin CR; Stieltjes H; Sha S; Weiner S; Devineni D
Clin Ther; 2015 Jul; 37(7):1483-1492.e1. PubMed ID: 26048186
[TBL] [Abstract][Full Text] [Related]
12. Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.
An JH; Choi HS; Choi JS; Lim HW; Huh W; Oh YI; Park JS; Han J; Lim S; Lim CY; Kim TH; Moon JB; Youn HY
Vet Med Sci; 2024 May; 10(3):e1454. PubMed ID: 38686463
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.
Komoroski B; Vachharajani N; Boulton D; Kornhauser D; Geraldes M; Li L; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):520-6. PubMed ID: 19129748
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
[TBL] [Abstract][Full Text] [Related]
15. Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants.
Devineni D; Polidori D; Curtin C; Stieltjes H; Tian H; Wajs E
Clin Ther; 2016 Jan; 38(1):89-98.e1. PubMed ID: 26687552
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.
Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y
Adv Ther; 2015 Apr; 32(4):319-40. PubMed ID: 25855342
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitus.
Li X; Zhu X; Liu J; Li Q; Zhang H; Li C; Wu M; Gao L; Wen H; Li X; Tang X; Liu L; Ding Y
Diabetes Obes Metab; 2020 Dec; 22(12):2316-2324. PubMed ID: 32744380
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin.
Lu J; Wang L; Zhou S; Zhou C; Xie L; Chen J; Tang D; Tian X; Xie D; Ding J; Wang T; Yu Q; Ding J; Shao F
Br J Clin Pharmacol; 2022 Jun; 88(6):2946-2958. PubMed ID: 34965609
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Komoroski B; Vachharajani N; Feng Y; Li L; Kornhauser D; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):513-9. PubMed ID: 19129749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
